Integrated from the Start: Unlocking the Full Potential of Continuous Manufacturing
Continuous manufacturing has long been the standard in many processing industries, offering clear advantages over traditional batch operations: faster throughput, reduced inventory, and greater consistency. In recent years, even the pharmaceutical sector, traditionally slow to embrace paradigm-shifting manufacturing technologies, has begun to embrace this approach, recognizing the potential to reduce cost, shorten timelines, and improve product quality.
Yet to capture the full benefits of continuous processing, it must be implemented in an integrated fashion, linking all unit operations into a seamless, end-to-end system. Running one or two steps continuously within an otherwise batch-based workflow does not change the underlying paradigm; the process still behaves like a batch system, with its associated inefficiencies and variability.
CONTINUUS Pharmaceuticals’ Integrated Continuous Manufacturing (ICM) platform is designed to overcome this limitation. Developed from foundational research at the Novartis–MIT Center for Continuous Manufacturing, the ICM system enables fully integrated production of small molecule drugs, from key starting materials (KSM) through final dosage form (FDF). Each unit operation has been purpose-built or adapted for 24-hour operation, supporting uninterrupted material flow, tight process control, and minimized manual intervention.
The ICM platform combines upstream active pharmaceutical ingredient (API) synthesis with downstream drug product formulation into a unified continuous line. It includes a plug-and-play suite of modular technologies, such as flow reactors, continuous crystallizers, rotary filtration units, drum dryers, extrusion-injection molding and solvent recovery systems, allowing configuration to meet the specific needs of each compound. Advanced process analytical technology (PAT) tools, including real-time pH, density, Raman, and infrared monitoring, feed into closed-loop control systems that maintain critical process parameters within tight specifications, ensuring consistent performance and high-quality output.
By integrating steps such as crystallization, filtration, drying, and formulation into a single continuous line, ICM eliminates unnecessary material handoffs, reduces hold times, and improves product uniformity. This level of integration also dramatically reduces the physical footprint required compared with traditional batch plants, which rely on large, segregated suites for each unit operation, staging, and storage. For companies reshoring or regionalizing supply chains, the smaller real estate and lower overhead requirements can translate into significant capital and operating savings, making domestic production more economically viable even in high-cost markets. This approach not only compresses production timelines but also improves scalability, sustainability, and regulatory transparency — advantages that can only be realized when continuous manufacturing is treated as a holistic strategy rather than a piecemeal upgrade.
Two Paths to Integration: Starting with Confidence or Scaling with Vision
Companies adopting continuous manufacturing for the first time generally face a choice of two primary strategic entry points. They can either reformulate an existing batch-based product with a new continuous process, or they can design and implement an integrated continuous process from the outset for a new drug candidate in early development.
Each route has distinct considerations. Reformulating an existing product requires post-approval changes, typically supported by bioequivalence studies to demonstrate equivalent product quality. While this path may appear complex from a regulatory standpoint, it benefits from the fact that the product itself is already approved, and safety and efficacy are not in question. This allows companies to “de-risk” the implementation of new technology by separating it from clinical uncertainty. For many manufacturers, this approach serves as a low-stakes proving ground for continuous processing and can build internal confidence in its capabilities.
However, the greatest strategic and operational benefits of integrated continuous manufacturing (ICM) are unlocked when the approach is introduced early in development. This allows companies to build a complete, scale-ready, and regulatory-aligned process from the beginning, streamlining every downstream stage. In addition to offering the smaller footprint, tighter process control, improved sustainability, and reduced batch-to-batch variability that all continuous systems promise, early integration delivers compounding efficiencies during scale-up and scale-out.
In traditional batch production, scaling often requires reengineering of unit operations, extended process development timelines, and additional clinical comparability studies. With ICM, scaling is far simpler: larger volumes are achieved by extending runtime, not by redesigning the process or moving to new equipment. Because the same integrated process is used from late-stage clinical through commercial manufacturing, companies avoid the delays and regulatory complexity that often accompany scale transitions. This continuity also ensures that critical quality attributes remain consistent, removing uncertainty and reducing the risk of regulatory setbacks.
Importantly, early adoption of ICM can also accelerate regulatory review. A recent U.S. Food and Drug Administration (FDA) study found that drugs manufactured with continuous processes benefited from shorter review timelines, a result attributed to the agency’s Emerging Technology Team, which facilitates more efficient engagement and review pathways for companies leveraging innovative manufacturing approaches. In practice, this has helped some small molecule developers reduce time to market by five to six months, a potentially decisive advantage in competitive therapeutic areas.
The benefits extend into the commercial phase as well. The modular design of the ICM platform enables flexible production, allowing manufacturers to rapidly adjust capacity in response to fluctuating demand, whether for seasonal products or unexpected surges in demand. Expanding into new markets is also streamlined: once a continuous process is validated, it can be replicated across regional sites without the need for new tech transfer programs. Additionally, mid-development formulation adjustments or post-launch life cycle updates can be incorporated more quickly and with fewer regulatory hurdles.
Ultimately, the decision of whether to begin with a legacy product or a development-stage candidate depends on a mix of organizational priorities, regulatory posture, and the specific characteristics of the molecule in question. Risk-tolerant innovators may opt to reap the full life cycle benefits from the start, while more conservative companies may prefer to validate the technology on an approved product first. In some cases, continuous manufacturing may be the only safe or practical route, such as with molecules that pose hazards or stability issues in batch settings but are amenable to continuous flow conditions.
Starting Small, Thinking Big: Stepwise Adoption as a Strategic On-Ramp
For many pharmaceutical companies, the shift from traditional batch manufacturing to a fully integrated continuous system represents a significant transformation. The move is not purely technological; it’s cultural, regulatory, and operational. Despite the growing body of evidence supporting continuous manufacturing, some firms remain hesitant, often due to concerns around regulatory risk, qualification complexity, or unfamiliarity with newer systems.
This is particularly true when the proposed system is as comprehensive as the CONTINUUS ICM platform. As a novel, end-to-end solution that integrates drug substance and drug product operations, the ICM system naturally invites scrutiny: Will it meet regulatory expectations? Can it be validated under existing frameworks? How will it interact with legacy infrastructure?
To address these concerns, the ICM platform has been designed with modularity at its core. Each unit operation — whether flow chemistry, crystallization, filtration, drying, or formulation — can operate independently or in combination with others. This enables a stepwise adoption model, where companies can begin with one or two continuous steps and progressively expand toward a fully integrated process as confidence builds and internal capabilities grow.
This flexibility lowers the barrier to entry, making it easier for manufacturers to test and validate continuous technologies without overhauling their entire production line. It also supports hybrid manufacturing models in the near term, allowing organizations to preserve existing infrastructure while positioning themselves for longer-term transformation.
Crucially, the anticipated regulatory validation of a first-to-market product manufactured with the full ICM platform will likely mark a turning point for industry adoption. Once marketing authorization is granted, other companies, especially those seeking to improve reliability, reduce cost, or differentiate through supply chain agility, will be more willing to invest in end-to-end integration.
A proven success story from leading early adopters — whether major innovators or top-tier pharma companies — will help overcome industry inertia and shift mindsets, catalyzing broader industry momentum. As more companies see real-world evidence of the quality, speed, and operational gains that fully integrated continuous manufacturing can deliver, adoption is expected to grow quickly.
Phasing In: How Continuous Manufacturing Evolves from Day One
ICM delivers its greatest strategic value when introduced early, especially during the transition from preclinical to clinical development. Because the system is inherently efficient at producing smaller quantities of high-quality material, it is particularly well suited for clinical manufacturing, where agility and precision are critical and waste must be minimized.
In practice, CONTINUUS typically recommends full end-to-end ICM implementation beginning at phase II, when the need for larger clinical batches begins to grow and consistent quality becomes even more important for downstream regulatory alignment. At this stage, the advantages of continuous processing — tight control, minimized variability, reduced footprint, and streamlined scale-out — translate directly into cost savings and faster timelines.
However, the transition starts earlier, often during phase I. Clinical materials for phase I trials are typically produced using a hybrid model: drug substance (API) might be synthesized using continuous flow chemistry, while downstream operations may still be handled in batch mode. This allows early experience with continuous operations while minimizing disruption. Preclinical material, by contrast, is usually produced entirely in batch.
Once a candidate progresses beyond phase I, a fully integrated, continuous end-to-end process is developed and implemented, aligning the manufacturing strategy with commercial readiness. This early adoption eliminates the need for tech transfer between development and commercial stages and supports a more predictable and efficient regulatory pathway.
By the time the product reaches late-stage development, the ICM process is well established and optimized, enabling faster scale-up, easier replication for global markets, and reduced time to market, all while maintaining tight control over critical quality attributes.
Lowering the Barrier with Clinical Manufacturing Support for Emerging Programs
CONTINUUS Pharmaceuticals was founded in 2012 with a clear and ambitious mission: to develop a fully integrated, end-to-end continuous manufacturing system for small molecule drugs. That vision has now been realized in the form of the ICM platform — a transformative technology that streamlines pharmaceutical production, shortens development timelines, and reduces the cost of delivering high-quality medicines to patients.
With this foundation in place, CONTINUUS is entering a new phase of growth, whereby it will enable pharmaceutical companies to implement the ICM processes in-house, while also providing services for both late stage clinical and commercial manufacturing in partnership with CDMOs. To bridge the gap into commercial services, CONTINUUS plans to launch early phase I clinical manufacturing capabilities by 2027, giving more drug developers access to the benefits of ICM without the capital burden of installing their own platform. A funding round to support this strategic expansion is planned for late 2025, aiming for the services to be fully operational and supporting customer programs by 2027. These services will provide phase I manufacturing support leveraging segments of the ICM platform, helping sponsors accelerate development while gaining familiarity with continuous manufacturing. For companies looking to de-risk their entry into ICM or evaluate its benefits before broader implementation, these services will offer a critical steppingstone.
By providing not just the technology but also hands-on support with early clinical manufacturing services, CONTINUUS aims to further lower the barrier to adoption and expand access to a more efficient, flexible, and scalable drug production model that is ready to meet the demands of modern drug development and the patients it serves.